New HIV protease inhibitors for drug-resistant viruses

Therapy

Volumn 3, Issue 1, 2006, Pages 79-88

  Rusconi, Stefano ^a   Viganò, Ottavia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Clinical efficacy; Drug resistance; HIV 1; Novel compounds; Protease inhibitors; Response

Indexed keywords

1 [3 BENZYL 3 (2,6 DIMETHYLPHENOXYACETAMIDO) 2 HYDROXYPROPYL] N TERT BUTYL 4 (4 PYRIDINYLTHIO)PIPECOLAMIDE; AG 001859; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BRECANAVIR; DARUNAVIR; GAG PROTEIN; INDINAVIR; LAMIVUDINE; LOPINAVIR; MOZENAVIR; NELFINAVIR; NEW DRUG; PALINAVIR; PL 100; PLACEBO; POL PROTEIN; PRODRUG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPI 70095; STAVUDINE; TIPRANAVIR; TMC 126; UIC 94003; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG STRUCTURE; FATIGUE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PRURITUS; REVIEW;

EID: 33646193492     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.3.1.79     Document Type: Review

References (74)

1. Boucher CAB, Tersmette M, Lange J et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336, 585-590 (1990).
2. Kahn JO, Lagakos SW, Richman DD et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N. Engl. J. Med. 327, 581-587 (1992).
3. D'Aquila RT, Hughes MD, Johnson VA et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann. Intern. Med. 124, 1019-1030 (1996).
4. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734 (1989).
5. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158 (1989).
6. Richman DD, Havlir D, Corbeil J et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68, 1660-1666 (1994).
7. Rusconi S, De Pasquale MP, Milazzo L et al. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1 infected patients in an ongoing open label trial. Antiviral Ther. 2, 41-48 (1997).
8. Roberts NA, Martin JA, Kinchington D, et al: Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358-361 (1990).
9. Kempf DJ, Marsh KC, Denissen JF et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl Acad Sci. USA 92, 2484-2488 (1995).
10. Vacca JP, Dorsey BD, Schleif WA et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl Acad. Sci. USA 91, 4096-4100 (1994).
11. Longer M, Shetty B, Zamansky I, Tyle P. Preformulation studies of a novel HIV protease inhibitor, AG1343. J. Pharm. Sci. 84, 1090-1093 (1995).
12. Kim EE, Baker CT, Dwyer MD et al. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117, 1181-1182 (1995).
13. Collier AC, Coombs RW, Schoenfeld DA et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334, 1011-1017 (1996).
14. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimiter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
15. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
16. Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 351, 543-549 (1998).
17. Zhang L, Ramratnam B, Tenner-Racz P et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
18. Furtado MR, Callaway DS, Phair JP et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614-1622 (1999).
19. Dornadula G, Zhang H, VanUitert B et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282, 1627-1632 (1999).
20. Coffin JM. HIV population dynamics in vivo: implications for genetic variations, pathogenesis, and therapy. Science 267, 483-489 (1995).
21. Condra JH, Emini EA. Preventing HIV-1 drug resistance. Science & Medicine 4, 14-23 (1997).
22. Condra JH. Schleif WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571 (1995).
23. Condra JH, Holder DJ, Schleif WA et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70, 8270-8276 (1996).
24. Winters MA, Schapiro JM, Lawrence J, Merigan TC. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitors susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J. Virol. 72, 5303-5306 (1998).
25. Dulioust A, Paolous S, Guillemot L, Delavalle A-M, Boué F, Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J. Virol. 73, 850-854 (1999).
26. Schapiro JM, Winters M, Lawrence J, Merigan TC. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic meutations. AIDS 13, 359-365 (1999).
27. Zolopa AR, Shafer RW, Warford A et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131, 813-821 (1999).
28. Hirsch MS, Brun-Vézinet F, D'Aquila RT et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283, 2417-2426 (2000).
29. Call SA, Saag MS, Westfan AO et al. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J. Infect. Dis. 183, 401-408 (2001).
30. Asamoah-Odei E, Garcia Calleja JM, Ties Boerma J. HIV prevalence and trends in sub-Saharan Africa: no decline and large subregional differences. Lancet 364, 35-40 (2004).
31. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860 (1998).
32. Berrey MM, Schacker T, Collier AC et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J. Infect. Dis. 83, 1466-1475 (2001).
33. Navia MA, Fitzgerald PMD, McKeever BM et al. Three-dimensional structure of aspartyl proetase from human immunodeficiency virus HIV-1. Nature 337, 625-630 (1989).
34. Condra JH. Virological and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist. Updates 1, 292-299 (1998).
35. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42, 2775-2783 (1998).
36. Schmit J-C, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10, 995-999 (1996).
37. Kaplan AH, Michael SF, Wehbie RS et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl Acad. Sci. USA 91, 5597-5601 (1994).
38. Molla A, Korneyeva M, Gao Q et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2, 760-766 (1996).
39. Chen Z, Li Y, Schock HB, Hall D, Chen E, Kuo LC. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270, 21433-21436 (1995).
40. Prabu-Jeyabalan MM, King NM, Malivaika E, Scott WRP, Shiffer C. Drug resistance and substrate recognition in HIV-1 protease. Antiviral Ther. 7, S36 (2002).
41. Markowitz M, Mo H, Kempf DJ et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69, 701-706 (1995).
42. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39, 1704-1710 (1995).
43. Miller V, Hertogs K, de Bèthune M-P et al. Incidence of HIV-1 resistance and cross-resistance to protease inhibitors after indinavir failure: Impact of subsequent ritonavir/saquinavir combination therapy. Proceedings of the International Workshop and HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, FL, USA, Abstract 81 (1997).
44. Poppe SM, Slade DE, Chong K-T et al. Antiviral activity of the dihydropyrone PNU-140690, a new non-peptidic HIV protease inhibitor. Antimicrob. Agents Chemother. 41, 1058-1063 (1997).
45. Larder BA. Hertogs K, Bloor S et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14, 1943-1948 (2000).
46. Rusconi S, La Seta Catamancio S, Citterio P et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. 44, 1328-1332 (2000).
47. Schapiro J, Cahn P, Trottier B et al. Effect of baseline genotype on response to tipranavir/ritonavir compared with standard-of-care comparator in treatment-experienced patients: the phase 3 RESIST-1 and -2 trials. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, Abstract 104 (2005).
48. Cooper D, Hicks C, Cahn P et al. 24-week RESIST study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimised background regimen. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, (2005) (Abstract 560).
49. Yoshimura K, Kato R, Kavlick MF et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76, 1349-1358 (2002).
50. Erickson J, Gulnik S, Suvorov L et al. A femtomolar HIV-1 protease inhibitor with subnanomolar activity against multidrug resistant HIV-1 strains. Proceedings of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, (2001) (Abstract 12).
51. Surleraux DLNG, de Kock HA, Verscueren WG et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J. Med. Chem. 48, 1965-1973 (2005).
52. Ghosh AK, Pretzer E, Cho H, Hussain KA, Düzgüne N. Antiviral actrivity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease. Antiviral Res. 54, 29-36 (2001).
53. Koh Y, Nakata H, Maeda K et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother, 47, 3123-3129 (2003).
54. De Meyer S, Azijn H, Surleraux D et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49, 2314-2321 (2005).
55. Katlama C, Berger D, Bellos N et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, (2005) (Abstract 164LB).
56. Arastéh K, Clumeck N, Pozniak A et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 19, 943-947 (2005).
57. 2 ligand for peptidomimetic-based HIV protease inhibitors. J. Med. Chem. 43, 1094-1108 (2000).
58. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71, 1089-1096 (1997).
59. Wang LH, Chittick GE, Patanella, JE, Miralles GD. Effects of a novel HIV-1 protease inhibitor (PI), DMP450, on the pharmacokinetics (PK) of indinavir (IDV) and saquinavir (SQV). Proceedings of the 40th InterScience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, (2000) (Abstract 1647).
60. Sierra J, Nino S, Volkow P et al. Preliminary profile of the antiviral activity, metabolic effects and safety of DMP-450, a novel cyclic urea protease inhibitor. Antiviral Ther. 5, 6 (2000).
61. Chittick GE, Wang LH, DeMasi RA, Miralles GD. Effects of a novel HIV-1 protease inhibitor (PI), DMP450, on cardiac tracing, serum lipids and glucose tolerance, as compared to indinavir (IDV). Proceedings of the 40th InterScience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, (2000) (Abstract 1648).
62. Ala PJ, Huston EE, Klabe RM et al. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36, 1573-1580 (1997).
63. Stranix BR, Sauvè G, Bouzide A et al. Lysine sulfonamides as novel HIV-protease inhibitors: Nε-disubstituted ureas. Bioorg. Med. Chem. Lett. 14, 3971-3974 (2004).
64. Sévigny G, Stranix BR, Parkin N, Lie Y, Yelle J. Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100. Antiviral Ther. 9, S14 (2004).
65. Wu JJ, Sévigny G, Stranix BR et al. PL-100 and its derivatives, a novel class of potent human immunodeficiency virus type 1 protease inhibitors: resistance profile and pharmacokinetics. Antiviral Ther. 10, S84 (2005).
66. Hammond J. Jackson L, Graham J et al. Antiviral activity and resistance profile of AG-001859, a novel HIV-1 protease inhibitor with potent activity against protease inhibitor-resistant strains of HIV. Antiviral Ther. 9, S17 (2004).
67. Hammond J, Jackson L, Graham J, Blair W, Patick A. In vitro selection and characterization of HIV with reduced sensitivity to AG-001859. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, (2005) (Abstract 561).
68. Hazen R, St Clair M, Hanlon M et al. GW0385, a broad-spectrum, ultrapotent inhibitor of wild-type and protease-inhibitor-resistant HIV-1. Proceedings of the 2nd IAS Conference on HIV pathogenesis and Treatment. Paris, France, (2003) (Abstract 541).
69. Reddy S, Ford SL, Stein DS et al. Single-dose safety and pharmacokinetics (PK) of GW640385X (385): and HIV-1 protease inhibitor (PI). Proceedings of the 43th InterScience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, (2003) (Abstract 1800).
70. Florance A, Elston R, Johnson M, Spreen W, St Clair M. Phenotypic and genotypic resistance to a new protease inhibitor, 640385, in HIV-1 virus samples from subjects failing amprenavir. Antiviral Ther. 9, S15 (2004).
71. Yates P, Hazen R, St Clair M, Boone L, Elston R. In vitro selection and characterization of resistance to the new HIV protease inhibitor GW640385. Antiviral Ther. 9, S16 (2004).
72. Ford S, Reddy S, Anderson M, Murray S, Ng-Cashin J, Johnson M. 640385, a novel HIV-1 protease inhibitor: safety and pharmacokinetics following repeat administration with and without ritonavir in healthy subjects. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, (2005) Abstract 563).
73. Gulnik SV, Afonina, EI, Yu B et al. Highly potent HIV protease inhibitors with broad activity against MDR strains. Antiviral Ther. 9, S14 (2004).
74. Kohlbrenner VM, Hall DB, Baxter J et al. Tipranavir (TPV) mutation score predicts virologic success in PI-experienced HIV-positive adults. Antivir. Res. 39, Abstract 40, (2004).